Abstract
Diabetic kidney disease (DKD) can lead to end-stage kidney disease (ESKD) and mortality, however, few mechanistic biomarkers are available for high risk patients, especially those without macroalbuminuria. Urine from participants with diabetes from Chronic Renal Insufficiency Cohort (CRIC), Singapore Study of Macro-Angiopathy and Reactivity in Type 2 Diabetes (SMART2D), and the Pima Indian Study determined if urine adenine/creatinine ratio (UAdCR) could be a mechanistic biomarker for ESKD. ESKD and mortality were associated with the highest UAdCR tertile in CRIC (HR 1.57, 1.18, 2.10) and SMART2D (HR 1.77, 1.00, 3.12). ESKD was associated with the highest UAdCR tertile in patients without macroalbuminuria in CRIC (HR 2.36, 1.26, 4.39), SMART2D (HR 2.39, 1.08, 5.29), and Pima Indian study (HR 4.57, CI 1.37-13.34). Empagliflozin lowered UAdCR in non-macroalbuminuric participants. Spatial metabolomics localized adenine to kidney pathology and transcriptomics identified ribonucleoprotein biogenesis as a top pathway in proximal tubules of patients without macroalbuminuria, implicating mammalian target of rapamycin (mTOR). Adenine stimulated matrix in tubular cells via mTOR and stimulated mTOR in mouse kidneys. A specific inhibitor of adenine production was found to reduce kidney hypertrophy and kidney injury in diabetic mice. We propose that endogenous adenine may be a causative factor in DKD.
Competing Interest Statement
K.S. reports serving as consultant for Visterra, Bayer, Sanofi, and receiving research support from Boerhinger-Ingelheim. K.S. also reports having equity in a startup company, SygnaMap. P.B. reports serving as a consultant for AstraZeneca, Bayer, Bristol-Myers Squibb, Boehringer Ingelheim, Eli-Lilly, LG Chemistry, Sanofi, Novo Nordisk, and Horizon Pharma. P.B. also serves on the advisory boards of AstraZeneca, Bayer, Boehringer Ingelheim, Novo Nordisk, and XORTX. K.R.T. reports other support from Eli Lilly; personal fees and other support from Boehringer Ingelheim; personal fees and other support from AstraZeneca; grants, personal fees and other support from Bayer AG; grants, personal fees and other support from Novo Nordisk; grants and other support from Goldfinch Bio; other support from Gilead; and grants from Travere outside the submitted work. R.G.N. and H.C.L. report no conflicts. J.H. reports serving as a consultant for Maze Therapeutics, Chinook Therapeutics, Renalytix AI, and Seattle Genetics. D.C. has received honoraria from Boehringer Ingelheim-Lilly, Merck, AstraZeneca, Sanofi, Mitsubishi-Tanabe, AbbVie, Janssen, Bayer, Prometric, BMS, Maze, CSL Behring, and Novo Nordisk. H.L.H. has received honoraria for participation in steering committees from AstraZeneca, Janssen, Eli-Lilly, Gilead, Bayer, Chinook, Novartis, and CSL Behring; honoraria for participation in advisory boards from AstraZeneca, Vifor, Novartis, NovoNordisk, and Idorsia; fees for consultancy from AstraZeneca, Travere Pharmaceuticals, Boehringer Ingelheim, and Novo Nordisk; and research grant support from AstraZeneca, Janssen, Boehringer Ingelheim and NovoNordisk. Honoraria are paid to his institution [University Medical Center Groningen].
Funding Statement
This study was funded by NIH (UH3DK114920, 5U2CDK114886, RO1DK110541).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Institutional Review Board of National Institute of Diabetes and Digestive and Kidney Diseases gave ethical approval for Pima Indians from the Gila River Indian Community in Arizona study. Scientific and Data Coordinating Center (University of Pennsylvania) gave ethical approval for Chronic Renal Insufficiency Cohort Study (CRIC). Singapore National Health care group gave ethical approval for The Singapore Study of Macro-angiopathy and Micro-vascular Reactivity in Type 2 Diabetes (SMART2D) study. Research Ethics Board at the University Health Network (Toronto, Canada) gave ethical approval for An Open-label 8-week Adjunctive-to-insulin and Renal Mechanistic Pilot Trial of BI 10773 in Type 1 Diabetes Mellitus (the ATIRMA Trial). Institutional Review Board of Washington University in St. Louis gave ethical approval for the Kidney Precision Medicine Project (KPMP) study. Institutional Review Board of the University of Colorado gave ethical approval for Control of Renal Oxygen Consumption, Mitochondrial Dysfunction, and Insulin Resistance (CROCODILE) study and written consent was obtained from all patients.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors.
Data Availability
All data produced in the present study are available upon reasonable request to the authors.
